‘Dangling’ Accelerated Approvals: US FDA Flags Concerns About ‘Marginal’ Response Rates

 
• By Sue Sutter
Dangling mugs
US FDA's Oncology Center of Excellence has coined the term "dangling accelerated approvals" when confirmatory trials fail to verify clinical benefit but indications remain on the label. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers